Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Non-cash Items: 2010-2018

Historic Non-cash Items for Vanda Pharmaceuticals (VNDA) over the last 5 years, with Mar 2018 value amounting to $3.3 million.

  • Vanda Pharmaceuticals' Non-cash Items fell 2.53% to $3.3 million in Q1 2018 from the same period last year, while for Mar 2018 it was $3.3 million, marking a year-over-year decrease of 2.53%. This contributed to the annual value of $3.5 million for FY2017, which is 89.09% down from last year.
  • According to the latest figures from Q1 2018, Vanda Pharmaceuticals' Non-cash Items is $3.3 million, which was down 86.39% from $24.4 million recorded in Q4 2017.
  • In the past 5 years, Vanda Pharmaceuticals' Non-cash Items ranged from a high of $3.3 billion in Q2 2017 and a low of $3.3 million during Q1 2018.
  • For the 3-year period, Vanda Pharmaceuticals' Non-cash Items averaged around $377.0 million, with its median value being $5.9 million (2016).
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Non-cash Items crashed by 88.45% in 2015, and later spiked by 75,048.18% in 2017.
  • Vanda Pharmaceuticals' Non-cash Items (Quarterly) stood at $28.5 million in 2014, then tumbled by 73.71% to $7.5 million in 2015, then spiked by 332.82% to $32.5 million in 2016, then decreased by 24.75% to $24.4 million in 2017, then decreased by 2.53% to $3.3 million in 2018.
  • Its last three reported values are $3.3 million in Q1 2018, $24.4 million for Q4 2017, and $37.4 million during Q3 2017.